Prognostic value of LISCH7 mRNA in plasma and tumor of colon cancer patients.
OBJECTIVE
LISCH7 is a gene potentially regulated by p53 that is up-regulated in metastasis development. Our hypothesis was that the expression of LISCH7 in primary colorectal tumors determined certain characteristics of the tumors, as well as their behavior, and that its identification in plasma could serve as a prognostic marker.


METHODS
We tested this hypothesis in a series of 115 tumors and normal tissues and in 83 plasmas from patients with sporadic colorectal carcinomas, as well as in 20 healthy control plasmas in which the expression levels of the gene were measured by real-time PCR. The expression data were contrasted with clinicopathologic variables.


RESULTS
Although LISCH7 expression was not detected in any control plasma samples, it was positive in 25 (30.1%) plasmas from patients (P = 0.002). LISCH7 mRNA in plasma was significantly associated with the pathologic stage (P = 0.019), with lymph node metastasis (P = 0.008) and with vascular invasion (P = 0.005). Expression was not detected in any normal tissues but was detected in 80 tumor tissues, with a clear association found with vascular invasion (P = 0.027). Moreover, we show that LISCH7 was specifically expressed by the epithelial tumor cells. The adjusted overall survival study showed independent prognostic values for LISCH7 expression levels in tumor tissues (hazard ratio, 3.45; 95% confidence interval, 1.19-9.98).


CONCLUSIONS
Our results suggest that LISCH7 is a good tumor marker whose expression levels could be considered as a poor prognosis factor in human colon cancer. Furthermore, plasma is suggested as a feasible source of nucleic acids for subsequent noninvasive prognostic studies.
García
José M
JM
Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Peña
Cristina
C
García
Vanesa
V
Domínguez
Gemma
G
Muñoz
Concepción
C
Silva
Javier
J
Millán
Isabel
I
Diaz
Raquel
R
Lorenzo
Yolanda
Y
Rodriguez
Rufo
R
Bonilla
Félix
F
D000368:Aged; D003110:Colonic Neoplasms / Q000097:blood* / Q000378:metabolism*; D004847:Epithelial Cells / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism*; D011973:Receptors, LDL / Q000097:blood* / Q000378:metabolism*; D018110:Receptors, Lipoprotein / Q000096:biosynthesis* / Q000235:genetics*; D014157:Transcription Factors / Q000096:biosynthesis* / Q000235:genetics*; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
C525854:LSR protein, human; D012333:RNA, Messenger; D011973:Receptors, LDL; D018110:Receptors, Lipoprotein; C495901:TP53 protein, human; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; C085992:lipolysis-stimulated receptor